28118773|t|Percutaneous microwave ablation with artificial ascites for symptomatic uterine adenomyosis: initial experience
28118773|a|To evaluate the feasibility, safety and technical efficacy of ultrasound-guided percutaneous microwave ablation with artificial ascites for adenomyosis. Between May 2015 and May 2016, a total of 25 patients with symptomatic adenomyosis who underwent ultrasound-guided percutaneous microwave ablation with artificial ascites were included in this retrospective study. A matching cohort of 50 patients underwent ultrasound-guided percutaneous microwave ablation without artificial ascites as controls. The technical efficacy, complications and short-term treatment effectiveness were assessed and compared with the controls. Artificial ascites was successfully achieved in all of the 25 patients with the administration of a median of 550 mL (range, 250-1200 mL) of solution. There was substantial improvement in achieving a better antenna path in 100% (20/20) of the cases with a poor antenna path. The complete separation was achieved in 23 of 25 patients. The mean ablation time was 26.5 ± 7.3 min and the median non-perfusion volume ratio was 76% which was similar to the control group (p > .05). No serious complications were observed. Patient pain scores for dysmenorrhoea showed a statistically significant decline from the baseline of 6.71 ± 0.96 to 2.92 ± 0.79 and the symptom severity score declined statistically significantly from 21.8 ± 5.5 to 16.4 ± 4.8 at 3 months follow-up. Percutaneous microwave ablation with artificial ascites is feasible, safe and can be effective in improving access for treatment of adenomyosis.
28118773	0	31	Percutaneous microwave ablation	T061	C3854551
28118773	37	47	artificial	T080	C2004457
28118773	48	55	ascites	T033	C0003962
28118773	60	91	symptomatic uterine adenomyosis	T047	C0341858
28118773	93	111	initial experience	T041	C0596545
28118773	115	123	evaluate	T058	C0220825
28118773	128	139	feasibility	T062,T170	C0015730
28118773	141	147	safety	T068	C0036043
28118773	152	161	technical	T169	C0449851
28118773	162	170	efficacy	T080	C1280519
28118773	174	223	ultrasound-guided percutaneous microwave ablation	T061	C3854551
28118773	229	239	artificial	T080	C2004457
28118773	240	247	ascites	T033	C0003962
28118773	252	263	adenomyosis	T047	C0341858
28118773	273	276	May	T079	C3812381
28118773	286	289	May	T079	C3812381
28118773	310	318	patients	T101	C0030705
28118773	324	347	symptomatic adenomyosis	T047	C0341858
28118773	362	411	ultrasound-guided percutaneous microwave ablation	T061	C3854551
28118773	417	427	artificial	T080	C2004457
28118773	428	435	ascites	T033	C0003962
28118773	458	477	retrospective study	T062	C0035363
28118773	481	489	matching	T062	C0150103
28118773	490	496	cohort	T098	C0599755
28118773	503	511	patients	T101	C0030705
28118773	522	571	ultrasound-guided percutaneous microwave ablation	T061	C3854551
28118773	580	590	artificial	T080	C2004457
28118773	591	598	ascites	T033	C0003962
28118773	602	610	controls	T096	C0009932
28118773	616	625	technical	T169	C0449851
28118773	626	634	efficacy	T080	C1280519
28118773	636	649	complications	T169	C1171258
28118773	654	664	short-term	T079	C0443303
28118773	665	688	treatment effectiveness	T080	C0087113
28118773	694	702	assessed	T052	C1516048
28118773	707	715	compared	T052	C1707455
28118773	725	733	controls	T096	C0009932
28118773	735	745	Artificial	T080	C2004457
28118773	746	753	ascites	T033	C0003962
28118773	771	779	achieved	T033	C0243095
28118773	797	805	patients	T101	C0030705
28118773	815	829	administration	T061	C1533734
28118773	835	841	median	T082	C0549183
28118773	876	884	solution	T122	C0525069
28118773	896	919	substantial improvement	T077	C2986411
28118773	923	932	achieving	T033	C0243095
28118773	942	954	antenna path	T082	C1254362
28118773	978	983	cases	T169	C0868928
28118773	996	1008	antenna path	T082	C1254362
28118773	1014	1033	complete separation	T169	C0205245
28118773	1038	1046	achieved	T033	C0243095
28118773	1059	1067	patients	T101	C0030705
28118773	1073	1091	mean ablation time	T079	C0040223
28118773	1119	1125	median	T082	C0549183
28118773	1126	1152	non-perfusion volume ratio	T081	C1547056
28118773	1186	1199	control group	T096	C0009932
28118773	1222	1235	complications	T169	C1171258
28118773	1251	1270	Patient pain scores	T033	C0582148
28118773	1275	1288	dysmenorrhoea	T046	C0013390
28118773	1298	1323	statistically significant	T081	C0237881
28118773	1324	1331	decline	T081	C0282251
28118773	1388	1410	symptom severity score	T081	C0457451
28118773	1411	1419	declined	T081	C0282251
28118773	1420	1447	statistically significantly	T081	C0237881
28118773	1483	1489	months	T079	C0439231
28118773	1501	1532	Percutaneous microwave ablation	T061	C3854551
28118773	1538	1548	artificial	T080	C2004457
28118773	1549	1556	ascites	T033	C0003962
28118773	1560	1568	feasible	T080	C0205556
28118773	1570	1574	safe	T033	C3266157
28118773	1586	1595	effective	T080	C1704419
28118773	1609	1615	access	T082	C0444454
28118773	1620	1629	treatment	T169	C0039798
28118773	1633	1644	adenomyosis	T047	C0341858